StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Intellia Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $346.73M, down 22.2% year over year. For fiscal 2025 it was $388.86M, down 16.6% from the year before. Over ten years it grew 42.6% a year on average. The highest annual figure on record is $466.31M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$388.86M-16.6%
FY2024Dec 31, 2024$466.31M+7.2%
FY2023Dec 31, 2023$435.07M+3.6%
FY2022Dec 31, 2022$419.98M+82.8%
FY2021Dec 31, 2021$229.81M+52.8%
FY2020Dec 31, 2020$150.41M+38.7%
FY2019Dec 31, 2019$108.41M+21.7%
FY2018Dec 31, 2018$89.12M+31.7%
FY2017Dec 31, 2017$67.65M+112.5%
FY2016Dec 31, 2016$31.84M+185.0%
FY2015Dec 31, 2015$11.17M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$82.60M-14.9%
Q1 FY2026Mar 31, 2026$80.74M-25.5%
Q4 FY2025Dec 31, 2025$88.65M-24.1%
Q3 FY2025Sep 30, 2025$94.75M-23.2%
Q2 FY2025Jun 30, 2025$97.04M-15.0%
Q1 FY2025Mar 31, 2025$108.43M-3.1%
Q4 FY2024Dec 31, 2024$116.88M+7.2%
Q3 FY2024Sep 30, 2024$123.38M+8.5%
Q2 FY2024Jun 30, 2024$114.21M-0.9%
Q1 FY2024Mar 31, 2024$111.85M+15.2%
Q4 FY2023Dec 31, 2023$108.98M+8.9%
Q3 FY2023Sep 30, 2023$113.70M+17.6%
Q2 FY2023Jun 30, 2023$115.28M+27.8%
Q1 FY2023Mar 31, 2023$97.12M-27.0%
Q4 FY2022Dec 31, 2022$100.03M+40.6%
Q3 FY2022Sep 30, 2022$96.65M+59.8%
Q2 FY2022Jun 30, 2022$90.20M+53.2%
Q1 FY2022Mar 31, 2022$133.10M+238.9%
Q4 FY2021Dec 31, 2021$71.16M+86.1%
Q3 FY2021Sep 30, 2021$60.49M+52.1%
Q2 FY2021Jun 30, 2021$58.88M+55.9%
Q1 FY2021Mar 31, 2021$39.28M+13.4%
Q4 FY2020Dec 31, 2020$38.23M+20.5%
Q3 FY2020Sep 30, 2020$39.76M+44.5%
Q2 FY2020Jun 30, 2020$37.77M+48.4%
Q1 FY2020Mar 31, 2020$34.65M+46.1%
Q4 FY2019Dec 31, 2019$31.73M+59.3%
Q3 FY2019Sep 30, 2019$27.51M+18.4%
Q2 FY2019Jun 30, 2019$25.46M+8.5%
Q1 FY2019Mar 31, 2019$23.71M+5.4%
Q4 FY2018Dec 31, 2018$19.92M-5.9%
Q3 FY2018Sep 30, 2018$23.24M+32.9%
Q2 FY2018Jun 30, 2018$23.47M+50.8%
Q1 FY2018Mar 31, 2018$22.49M+67.5%
Q4 FY2017Dec 31, 2017$21.17M+86.8%
Q3 FY2017Sep 30, 2017$17.48M+122.4%
Q2 FY2017Jun 30, 2017$15.57M–
Q1 FY2017Mar 31, 2017$13.43M–
Q4 FY2016Dec 31, 2016$11.33M–
Q3 FY2016Sep 30, 2016$7.86M–

More Intellia Therapeutics figures

See a number that looks wrong?